Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 9 | 2021 | 207 | 1.170 |
Why?
|
| Islets of Langerhans Transplantation | 5 | 2012 | 174 | 0.450 |
Why?
|
| Islets of Langerhans | 3 | 2012 | 271 | 0.410 |
Why?
|
| Pancreatic Ducts | 2 | 2008 | 30 | 0.350 |
Why?
|
| Tissue Donors | 3 | 2023 | 143 | 0.340 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2021 | 83 | 0.320 |
Why?
|
| Kidney Neoplasms | 2 | 2021 | 125 | 0.310 |
Why?
|
| Donor Selection | 2 | 2018 | 16 | 0.310 |
Why?
|
| Interleukin-8 | 1 | 2008 | 87 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 197 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2012 | 605 | 0.260 |
Why?
|
| Frailty | 2 | 2018 | 124 | 0.250 |
Why?
|
| Lithotripsy, Laser | 1 | 2023 | 2 | 0.210 |
Why?
|
| Kidney Calculi | 1 | 2023 | 17 | 0.210 |
Why?
|
| Hepatitis A | 1 | 2020 | 8 | 0.180 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 16 | 0.180 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 100 | 0.170 |
Why?
|
| Liver | 3 | 2018 | 795 | 0.160 |
Why?
|
| Kidney Transplantation | 2 | 2019 | 313 | 0.160 |
Why?
|
| Telepathology | 1 | 2018 | 6 | 0.160 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 12 | 0.150 |
Why?
|
| Clinical Enzyme Tests | 1 | 2018 | 12 | 0.150 |
Why?
|
| Liver Failure | 1 | 2018 | 17 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 29 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2003 | 427 | 0.150 |
Why?
|
| Liver Function Tests | 1 | 2018 | 36 | 0.150 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 38 | 0.150 |
Why?
|
| Sarcopenia | 1 | 2018 | 18 | 0.150 |
Why?
|
| Hepatitis | 1 | 2018 | 55 | 0.150 |
Why?
|
| Smartphone | 1 | 2018 | 65 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 206 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2023 | 5281 | 0.130 |
Why?
|
| Mobile Applications | 1 | 2018 | 129 | 0.130 |
Why?
|
| Health Care Rationing | 1 | 2016 | 21 | 0.130 |
Why?
|
| Waiting Lists | 1 | 2016 | 48 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2017 | 143 | 0.120 |
Why?
|
| Kidney | 1 | 2017 | 414 | 0.120 |
Why?
|
| Health Policy | 1 | 2016 | 177 | 0.110 |
Why?
|
| Humans | 18 | 2023 | 59389 | 0.110 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 365 | 0.110 |
Why?
|
| Male | 12 | 2021 | 27747 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 276 | 0.100 |
Why?
|
| Graft Survival | 3 | 2018 | 290 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 263 | 0.100 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2012 | 87 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1479 | 0.090 |
Why?
|
| Middle Aged | 8 | 2021 | 16314 | 0.090 |
Why?
|
| Lymphocyte Count | 1 | 2009 | 68 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 527 | 0.080 |
Why?
|
| Chorioallantoic Membrane | 1 | 2008 | 2 | 0.080 |
Why?
|
| Chick Embryo | 1 | 2008 | 42 | 0.080 |
Why?
|
| C-Peptide | 2 | 2009 | 23 | 0.070 |
Why?
|
| Adult | 7 | 2019 | 15683 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2008 | 81 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 178 | 0.070 |
Why?
|
| Rats, Wistar | 1 | 2008 | 179 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 101 | 0.070 |
Why?
|
| Female | 9 | 2019 | 30724 | 0.070 |
Why?
|
| Pancreas Transplantation | 1 | 2006 | 20 | 0.070 |
Why?
|
| Mice, Inbred NOD | 1 | 2008 | 516 | 0.070 |
Why?
|
| Tacrolimus | 2 | 2021 | 62 | 0.070 |
Why?
|
| Mycophenolic Acid | 2 | 2021 | 66 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2008 | 2092 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 689 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2018 | 6071 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1027 | 0.060 |
Why?
|
| Gene Expression | 1 | 2008 | 809 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 986 | 0.060 |
Why?
|
| Rats | 1 | 2008 | 1910 | 0.060 |
Why?
|
| Thromboplastin | 1 | 2004 | 6 | 0.060 |
Why?
|
| Cytokines | 1 | 2008 | 915 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2006 | 461 | 0.060 |
Why?
|
| Ureteroscopy | 1 | 2023 | 6 | 0.050 |
Why?
|
| Portal System | 1 | 2003 | 3 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 410 | 0.050 |
Why?
|
| Perfusion | 1 | 2023 | 79 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 223 | 0.050 |
Why?
|
| Insulin | 3 | 2012 | 673 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2021 | 53 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 28 | 0.040 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.040 |
Why?
|
| Candida | 1 | 2020 | 35 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 337 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 102 | 0.040 |
Why?
|
| Aged | 4 | 2019 | 13406 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 44 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 120 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 191 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2019 | 66 | 0.040 |
Why?
|
| Adolescent | 3 | 2016 | 5838 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 658 | 0.040 |
Why?
|
| Mice | 2 | 2012 | 10294 | 0.040 |
Why?
|
| Primary Graft Dysfunction | 1 | 2018 | 4 | 0.040 |
Why?
|
| Risk Factors | 2 | 2018 | 4986 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2018 | 365 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 61 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 423 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 5119 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 4272 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2016 | 93 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1597 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 52 | 0.030 |
Why?
|
| Critical Care | 1 | 2020 | 397 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 199 | 0.030 |
Why?
|
| United States | 2 | 2019 | 7426 | 0.030 |
Why?
|
| Animals | 2 | 2012 | 19650 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1559 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 814 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 1234 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1307 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 2375 | 0.030 |
Why?
|
| Massachusetts | 1 | 2018 | 2019 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 190 | 0.020 |
Why?
|
| Immune System | 1 | 2012 | 129 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 3615 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 559 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2009 | 20 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 326 | 0.020 |
Why?
|
| Reoperation | 1 | 2009 | 272 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 451 | 0.020 |
Why?
|
| Organ Size | 1 | 2006 | 164 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 1099 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3231 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2009 | 480 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2004 | 5 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 801 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 645 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 847 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 2338 | 0.010 |
Why?
|